ten23 health announces major expansion in Switzerland with two new sterile manufacturing lines


The dedicated 5000 square metre facility will provide an additional 30+ million units/year of fill and finish capacity

ten23 health, a global contract development and manufacturing organisation (CDMO) has announced an additional expansion of swissfillon’s manufacturing site in Visp, canton of Valais, Switzerland, which was acquired October 2021.

The FDA- and Swissmedic-inspected site in Visp currently offers sterile manufacturing of prefilled syringes, vials and cartridges for clinical trial and market supplies.

Today’s announcement concerns the set-up of a new manufacturing building in Visp-West, fully dedicated to ten23 health, which will provide around 5000 square metres of space on 4 floors. It has the capacity to accommodate a total of three additional manufacturing lines, technical areas and offices and laboratories. The superstructure of the building will be completed in summer 2022.

In this new facility in Visp-West, ten23 health plans to build two further sterile manufacturing lines: sterile manufacturing line 2 will be a true scaled-up version of our existing filling line 1 and provide GMP fill & finish capacity for commercial as well as clinical use.

The fill line will be based on latest Isolator technology and will be able to handle ready-to-use (RTU) containers including syringes, cartridges and special primary packaging such as used in specific administration devices for subcutaneous delivery.

The annual total capacity of this line is estimated at 20 million units and the line is planned to be operational in 2024. Fill line 3 will broaden ten23 health’s offering and capabilities with the ability to fill bulk containers (vials), both in liquid and lyophilised form, with two larger-scale freeze-driers, each at 12.5 square metres of shelf-space, for both clinical and commercial use. The annual total capacity of this line is estimated at 12.5 million units.

The two additional manufacturing lines will have great synergy with the existing production line in Visp, the development and testing services for sterile products in Basel, Switzerland as well as the expansion we announced on 28 March 2022 related to the addition of 1000 square metres of cleanroom space for visual inspection and cold storage and supplementary services, such as device assembly.

The new building and production lines in Visp have the capacity to create more than 100 additional jobs in the region.

Sign up for your free email newsletter

Prof. Dr Hanns-Christian Mahler, CEO of ten23 health, commented: “The significant expansion of our production capacity for syringe and capsule filling, and technical capabilities of filling and lyophilization of sterile products in bulk vials is a clear commitment for Switzerland, and will enable our customers to provide treatment options for their patients.”